Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Human appetite control by glucagon-like peptide receptor binding compounds

a glucagon-like peptide and receptor-binding technology, applied in the field of appetite control, can solve the problems of major uncertainty whether glp-1 is safe for humans, functional deterioration, and the pursuit of further investigation of glp-1 for humans, so as to reduce spontaneous food intake, control appetite, and control appetite

Inactive Publication Date: 2006-06-15
AMYLIN PHARMA INC
View PDF7 Cites 26 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent text describes a composition that contains a compound that binds to a receptor for glucagon-like peptide-1, which is a protein involved in controlling appetite. When this composition is administered to humans, it can help control appetite and reduce spontaneous food intake. This is especially useful for individuals with diabetes.

Problems solved by technology

These inconsistent studies have discouraged further investigation of GLP-1 for humans.
Thus, the GLP-1 receptor is present at sites where administration of exogenous GLP-1 appears to cause satiety; however, whether it is a satiety factor has not been confirmed.
Accordingly, there would be an expected major uncertainty whether GLP-1 could counteract this stimulation and deliver appetite control.
Secondly, diabetics are characterized by having hyperglycemia, which in many causes a functional deterioration of the autonomous neural control systems for the GI tract, and in later stages causes structural damage to these systems.
Accordingly, there would be an expected major uncertainty whether GLP-1 could have an appetite control function in such diabetics.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human appetite control by glucagon-like peptide receptor binding compounds
  • Human appetite control by glucagon-like peptide receptor binding compounds
  • Human appetite control by glucagon-like peptide receptor binding compounds

Examples

Experimental program
Comparison scheme
Effect test

example 2

[0064] Twelve male patients were recruited for the study who had diabetes mellitus type 2 for at least one year. Patients were admitted to a Research Unit after given written informed consent and after the experimental protocol had been explained to them. The mean age of the patients was 55±2 years; their mean HbA1C was 8.1±4 and their mean BMi was 29.4±1.2. Seven patients were on oral antidiabetics. The participants were tested on two different days in a placebo-controlled, randomized, double-blind, crossover study. The two test days were separated by at least one week and by no more than three weeks.

[0065] On each test day, patients arrived in the Research Unit in the morning, having fasted overnight. A standardized, fixed energy breakfast was then served and it had to be completed before 8:30 a.m. After breakfast, patients were able to read and listen to music. At 11:00 a.m., two venflon catheters were inserted into the anticubital veins of each arm, one for infusion, the other ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
concentrationsaaaaaaaaaa
chromatographyaaaaaaaaaa
hydrophobic interaction chromatographyaaaaaaaaaa
Login to View More

Abstract

A composition including a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier. The amount of the compound present is effective to control appetite in a human. Also disclosed is a method for controlling appetite and for reducing food intake in a human by administering to the human a composition comprising a compound which binds to a receptor for glucagon-like peptide-1 and a pharmaceutical carrier.

Description

CROSS REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. application Ser. No. 09 / 646,433, filed 24 Nov. 2000, which is a National Stage Entry of PCT / US99 / 05571, filed 16 Mar. 1999, now WO 99 / 47161, which claims the benefit of U.S. Provisional Application No. 60 / 078,544, filed 19 Mar. 1998. The contents of each of the above-referenced applications are incorporated by reference in their entirety.FIELD OF THE INVENTION [0002] The present invention relates to the field of appetite control, and more particularly to compositions and methods where a glucagon-like peptide affects appetite suppression in humans, especially in humans with diabetes. BACKGROUND OF THE INVENTION [0003] The physiological mechanisms that produce satiety after food intake have not yet been defined. Several peptides normally secreted from the gastrointestinal tract during eating have been shown to suppress food intake if given before meals (Smith, G. P. and J. Gibbs. In: Martin J B, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/26
CPCA61K38/26Y10S514/809
Inventor GOKE, BURKHARDBEGLINGER, CHRISTOPHCOOLIDGE, THOMAS
Owner AMYLIN PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com